Immunovant, Inc. (IMVT)
- Previous Close
25.39 - Open
25.41 - Bid 25.47 x 100
- Ask 32.62 x 200
- Day's Range
25.18 - 26.47 - 52 Week Range
18.16 - 45.58 - Volume
775,193 - Avg. Volume
1,190,690 - Market Cap (intraday)
3.727B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-1.88 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
51.23
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
immunovant.comRecent News: IMVT
Performance Overview: IMVT
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMVT
Valuation Measures
Market Cap
3.71B
Enterprise Value
3.07B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.00
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.50%
Return on Equity (ttm)
-52.91%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-259.34M
Diluted EPS (ttm)
-1.88
Balance Sheet and Cash Flow
Total Cash (mrq)
635.36M
Total Debt/Equity (mrq)
0.02%
Levered Free Cash Flow (ttm)
--